肺がんゲノム検査市場：技術、サンプルタイプ、パネルタイプ、エンドユーザー別-2025-2030年の世界予測

肺がんゲノム検査市場は、2023年に10億1,000万米ドルと評価され、2024年には10億7,000万米ドルに達すると予測され、CAGR 8.00%で成長し、2030年には17億3,000万米ドルになると予測されています。

肺がんゲノム検査は個別化医療における重要なセグメントであり、肺がんに関連する遺伝子変異の同定を支援します。肺がんにおけるゲノム検査の必要性は、治療を調整し、病気の進行を予測し、患者の転帰を改善する能力によって推進され、腫瘍医、ヘルスケアプロバイダー、研究者に役立っています。アプリケーションの範囲は、診断ラボ、病院、精密医療に重点を置く研究機関を含みます。主な成長要因としては、肺がんの有病率の上昇、シーケンス技術の進歩、個別化治療オプションに対する意識の高まりなどが挙げられます。新たなビジネスチャンスは

市場力学：急速に進化する肺がんゲノム検査市場の主要市場インサイトを公開

肺がんゲノム検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加するがん罹患数
  • 肺がん治療へのアクセスを拡大する政府の取り組み
  • がんの治療と予防を拡大するための研究活動と共同研究の増加
• 市場抑制要因
  • 遺伝子検査サービスの高コストと償還不足
• 市場機会
  • 次世代ゲノムシーケンスの進歩
  • 個別化医療とバイオマーカー検査の採用傾向
• 市場の課題
  • 遺伝子・分子検査に関する厳しい規制

ポーターのファイブフォース：肺がんゲノム検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肺がんゲノム検査市場における外部からの影響の把握

外部マクロ環境要因は、肺がんゲノム検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肺がんゲノム検査市場における競合情勢の把握

肺がんゲノム検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肺がんゲノム検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肺がんゲノム検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肺がんゲノム検査市場における成功への道筋を描く

肺がんゲノム検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんの発症数が増加
    • 肺がん治療へのアクセス拡大に向けた政府の取り組み
    • がん治療と予防を拡大するための調査活動と協力の増加
  • 抑制要因
    • 遺伝子検査サービスの高コストと償還の欠如
  • 機会
    • 次世代ゲノムシークエンシングの進歩
    • 個別化医療とバイオマーカー検査の導入への傾向
  • 課題
    • 遺伝子検査および分子検査に関する厳格な規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肺がんゲノム検査市場：技術別

• 蛍光in situハイブリダイゼーション
• 次世代シーケンシング
• ポリメラーゼ連鎖反応

第7章 肺がんゲノム検査市場サンプルタイプ別

• 液体生検
• 組織生検

第8章 肺がんゲノム検査市場パネルタイプ別

• マルチ遺伝子パネル
• 単一遺伝子パネル

第9章 肺がんゲノム検査市場：エンドユーザー別

• 診断検査室
• 病院/診療所
• 調査組織

第10章 南北アメリカの肺がんゲノム検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の肺がんゲノム検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの肺がんゲノム検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Admera Health
• Agilent Technologies, Inc.
• BGI
• CD Genomics
• CeGaT GmbH
• Centogene N.V.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories
• OncoDNA
• OPKO Health, Inc.
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific, Inc.
• Veracyte, Inc.

LIST OF FIGURES

• FIGURE 1. LUNG CANCER GENOMIC TESTING MARKET RESEARCH PROCESS
• FIGURE 2. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LUNG CANCER GENOMIC TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MULTI-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SINGLE-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 190. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Lung Cancer Genomic Testing Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.07 billion in 2024, and is projected to grow at a CAGR of 8.00%, to USD 1.73 billion by 2030.

Lung cancer genomic testing is a crucial segment within personalized medicine, aiding in the identification of genetic mutations associated with lung cancer. The need for genomic testing in lung cancer is driven by its ability to tailor treatments, predict disease progression, and enhance patient outcomes, serving oncologists, healthcare providers, and researchers. The application scope encompasses diagnostic labs, hospitals, and research institutes focusing on precision medicine. Key growth factors include the rising prevalence of lung cancer, advancements in sequencing technologies, and increasing awareness of personalized treatment options. Emerging opportunities are

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of cancer incidences across the world
  • Government initiatives to expand access to lung cancer treatment
  • Growing number of research activities and collaborations to expand cancer care and prevention
• Market Restraints
  • High cost of genetic testing services and the lack of reimbursement
• Market Opportunities
  • Advancements in next-generation genome sequencing
  • Inclination toward adoption of personalized medicine and biomarker testing
• Market Challenges
  • Stringent regulations concerning genetic and molecular testing

Porter's Five Forces: A Strategic Tool for Navigating the Lung Cancer Genomic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lung Cancer Genomic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lung Cancer Genomic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lung Cancer Genomic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lung Cancer Genomic Testing Market

A detailed market share analysis in the Lung Cancer Genomic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lung Cancer Genomic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lung Cancer Genomic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lung Cancer Genomic Testing Market

A strategic analysis of the Lung Cancer Genomic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Genomic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Admera Health, Agilent Technologies, Inc., BGI, CD Genomics, CeGaT GmbH, Centogene N.V., F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, OncoDNA, OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Genomic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Fluorescence In Situ Hybridization, Next-Generation Sequencing, and Polymerase Chain Reaction.
• Based on Sample Type, market is studied across Liquid Biopsy and Tissue Biopsy.
• Based on Panel Type, market is studied across Multi-Gene Panel and Single-Gene Panel.
• Based on End User, market is studied across Diagnostic Laboratories, Hospitals/Clinics, and Research Organization.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of cancer incidences across the world
    • 5.1.1.2. Government initiatives to expand access to lung cancer treatment
    • 5.1.1.3. Growing number of research activities and collaborations to expand cancer care and prevention
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of genetic testing services and the lack of reimbursement
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in next-generation genome sequencing
    • 5.1.3.2. Inclination toward adoption of personalized medicine and biomarker testing
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations concerning genetic and molecular testing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Lung Cancer Genomic Testing Market, by Technology

• 6.1. Introduction
• 6.2. Fluorescence In Situ Hybridization
• 6.3. Next-Generation Sequencing
• 6.4. Polymerase Chain Reaction

7. Lung Cancer Genomic Testing Market, by Sample Type

• 7.1. Introduction
• 7.2. Liquid Biopsy
• 7.3. Tissue Biopsy

8. Lung Cancer Genomic Testing Market, by Panel Type

• 8.1. Introduction
• 8.2. Multi-Gene Panel
• 8.3. Single-Gene Panel

9. Lung Cancer Genomic Testing Market, by End User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals/Clinics
• 9.4. Research Organization

10. Americas Lung Cancer Genomic Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Lung Cancer Genomic Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Lung Cancer Genomic Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Admera Health
• 3. Agilent Technologies, Inc.
• 4. BGI
• 5. CD Genomics
• 6. CeGaT GmbH
• 7. Centogene N.V.
• 8. F. Hoffmann-La Roche AG
• 9. Illumina, Inc.
• 10. Laboratory Corporation of America Holdings
• 11. NeoGenomics Laboratories
• 12. OncoDNA
• 13. OPKO Health, Inc.
• 14. QIAGEN N.V.
• 15. Quest Diagnostics Incorporated
• 16. Thermo Fisher Scientific, Inc.
• 17. Veracyte, Inc.